Differential regulation of brain-derived neurotrophic factor (BDNF) expression in sensory neuron axons by miRNA-206

Shiva Shrestha1,2,3, Monichan Phay1,2, Hak Hee Kim1, Pedram Pouladvand2,4, Seung Joon Lee5 and Soonmoon Yoo1,2

1 Nemours Biomedical Research, Alfred I. duPont Hospital for Children, Wilmington, DE, USA
2 Department of Biological Sciences, University of Delaware, Newark, DE, USA
3 Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
4 Department of Biology, Pennsylvania State University-Brandywine, Media, PA, USA
5 Department of Biological Sciences, University of South Carolina, Columbia, SC, USA

Keywords
3' UTR variants; BDNF mRNA; brain-derived neurotrophic factor; differential regulation; dorsal root ganglion; miRNA-206; mRNA localization; sensory neuron; small non-coding microRNA

Correspondence
S. Yoo, Nemours Biomedical Research, Alfred I. duPont Hospital for Children, 1600 Rockland Rd, Wilmington, DE 19803, USA
Tel: +1 302 298 7006
E-mail: syoo@nemours.org

(Received 3 November 2018, revised 17 December 2018, accepted 20 December 2018)

doi:10.1002/2211-5463.12581

Brain-derived neurotrophic factor (BDNF) is a secreted protein of the neurotrophin family that plays crucial roles in the development and survival of neurons, growth of neuronal processes and synaptic plasticity [1–4]. An aberrant level of BDNF expression is closely associated with the pathophysiology of numerous neurological disorders including Alzheimer’s disease, Parkinson’s disease and Huntington’s disease [5–9]. Therefore, the expression of BDNF is tightly regulated by many processes at both the transcriptional and post-transcriptional levels. Although much is known about how the levels of BDNF transcript are regulated by diverse promoters, DNA methylation and alternative splicing, detailed mechanisms of post-transcriptional regulation, such as subcellular localization and translation, still remain to be clarified.

At the post-transcriptional level, the primary BDNF transcript generates two different 3’ UTR variants of BDNF mRNA, a short (0.35 kb) or a long 3’ UTR (2.9 kb), as a result of two alternative polyadenylation signals present in the 3’ coding exon [1,10,11]. The distinct 3’ UTR variants of BDNF mRNAs provide a distinct subcellular localization and subsequent translational control of 3’ UTR variants of mRNA encoding brain-derived neurotrophic factor (BDNF) are critical for the development and plasticity of neurons. Although the processes that lead to preferential localization of BDNF have been well studied, it is still not clear how neurons ensure differential BDNF production in a spatial-specific manner. Here, we identified that microRNA (miRNA)-206 has the potential to specifically regulate BDNF with a long 3’ UTR without affecting its short 3’ UTR counterpart. Over-expression of miRNA-206 in sensory neurons resulted in a 30% and 45% reduction of BDNF protein expression in the cell bodies and axons, respectively. The work described in the present study indicates that miRNAs can differentially and specifically regulate the expression of transcript variants with different localization patterns.

Abbreviations
BDNF, brain-derived neurotrophic factor; ddPCR, droplet digital PCR; DRG, dorsal root ganglion; ErbB3, receptor tyrosine-protein kinase ErbB family-3; FRAP, fluorescence recovery after photobleaching; GFAP, glial fibrillary acid protein; H1F0, H1 histone family member 0; MAP2, microtubule-associated protein 2; miRNA, microRNA; ROI, region of interest.
means to control BDNF expression via mRNA localization and/or translational control [10,12]. The short 3' UTR variant of BDNF mRNA is reported to be restricted in the soma and the long variant is preferentially transported to dendrites, contributing to the activity-dependent rapid increase in local expression [12]. These studies indicate that the 3' UTR of BDNF mRNA may play important roles in both mRNA localization and regulation of translation.

Recently, small non-coding RNAs such as micro-RNAs (miRNAs) have been found to mediate the control of key genes involved in the nervous system, suggesting that miRNAs have a role as key regulators in BDNF expression at the post-transcriptional level. However, it is still unclear how translation of these 3' UTR variants of the transcripts is differentially regulated in a spatial-specific manner. The targeting sites that miRNAs recognize and make base-pairing are often present within the 3' UTR of target mRNAs [13–15]. Recently, Lee et al. [16] showed that aberrantly high levels of miRNA-206 in Alzheimer diseased brains are directly involved in the pathogenesis of Alzheimer disease by targeting the 3' UTR of BDNF mRNA, suggesting that BDNF expression is post-transcriptionally regulated by miRNA-206. Therefore, we hypothesized that the long 3' UTR variant of BDNF mRNA could be subjected to the differential regulation by specific miRNAs from the counterpart with a short 3' UTR in a spatial-specific manner.

In the present study, we show that the long 3' UTR variant of BDNF mRNA is endogenously present in axons of sensory neurons, although with very low abundance. The miRNA-206 specifically regulated this variant of BDNF mRNA in axons. The transfection of miRNA-206 in primary culture of dorsal root ganglion (DRG) neurons from adult rats resulted in a significant reduction of BDNF protein. Overall, our findings demonstrate a unique ability of miRNA-206 in the selective regulation of intra-axonal translation via the targeting specific sequences only present in localizing BDNF mRNA with a long 3' UTR.

**Materials and methods**

**Animal use**

Animal procedures were approved by the Institutional Animal Care and Use Committees (IACUC) at the Nemours/Alfred I. duPont Hospital for Children, and the experiments were conducted under the IACUC at Alfred I. duPont Hospital for Children. Sprague–Dawley rats (weighing 150–225 g) were killed by asphyxiation with CO₂ using compressed sources of gas. When dead, rat tissues, including the brain, DRG and sciatic nerves, were surgically removed from the rat and the carcasses were disposed in conformance with regulations.

**RNA extraction and quantification**

Total RNA from rat L4–L6 DRGs and brain was isolated using phenol-chloroform extraction followed by ethanol precipitation. To isolate the axoplasm from the rat sciatic nerve, a mechanical squeezing method was used, as described previously [17]. Briefly, the sciatic nerves were cleaned from the surrounding connective tissues using ultrafine forceps in cold phosphate-buffered saline. The sciatic nerve was cut into segments of approximately 10 mm in length using a surgical blade. Then, the axoplasm was carefully squeezed manually using a pestle fit into a 1.5 mL microcentrifuge tube containing the lysis buffer on ice. Nucleic acids were isolated with the RNasequeous™-Micro Total RNA Isolation kit (Ambion, Austin, TX, USA). The concentration of RNA extracted was determined by the VersaFluor™ fluorometer (Bio-Rad, Hercules, CA, USA) using RiboGreen™ reagent (Invitrogen, Carlsbad, CA, USA) and then stored at −80 °C until use.

**cDNA synthesis and axoplasm RNA purity**

Five hundred nanograms of RNA was reverse-transcribed to cDNA using an iScript™ cDNA Synthesis Kit (Bio-Rad) in accordance with the manufacturer's instructions. To confirm the purity of the extracted axoplasmic RNA, an extended RT-PCR method (40 cycles) was utilized to check contamination from cell bodies and non-neuronal cells, including glial cells. RNA was considered as highly enriched axoplasmic RNA and used for further studies only when axoplasmic RNA samples were not detected for cell body-restricted microtubule-associated protein 2 (MAP2) and H1 histone family member 0 (H1F0), non-neuronal glial fibrillary acid protein (GFAP) and receptor tyrosine-protein kinase ErbB family member-3 (ErbB3) mRNAs (Fig. 1A). In addition, the presence of β-actin mRNA in the sample was indicative of the presence of mRNA in the extraction.

**Droplet digital PCR (ddPCR)**

ddPCR is a technological refinement of the conventional PCR method that uses a water–oil emulsion droplet system to partition a PCR sample into nanoliter-size samples and encapsulate them into oil droplets. The protocols that were followed were as described previously [18]. Briefly, cDNAs of DRG (soma) or sciatic axoplasm were mixed with the QX200 ddPCR EvaGreen Supermix (Bio-Rad) and specific primers for rat Nav1.6, Nav1.7, Nav1.8, BDNF long 3' UTR, BDNF coding region, neuritin 1 (Nrn1), Gap43 and amphoterin (also called Hmgb1) mRNAs (Integrated DNA Technologies).
The PCR reactions were then placed in a droplet generator system that partitions the reaction into 20,000 nL sized oil-based droplets followed by PCR amplification in accordance with the manufacturer’s instructions. Copy numbers of target mRNAs in units of copies per input sample were determined using QUANTASOFT (Bio-Rad) to provide an absolute quantification of target DNA copies per input sample. To account for copy number variations in axoplasmic and somal RNA samples between biological samples, target mRNA copy numbers were normalized with the copy numbers of amphoterin mRNA because this was previously shown to be constitutively transported into axons of adult DRG neurons without changes in expressed mRNA level upon nerve injury [18,19].

The relative ratio (R.R) of target mRNA levels in axon to those in soma were calculated as: 
\[ R.R = \frac{\text{gene}_{\text{axon}}/\text{amphoterin}_{\text{axon}}}{\text{gene}_{\text{soma}}/\text{amphoterin}_{\text{soma}}} \]

**DNA constructs**

3’ UTR variants (a long and a short 3’ UTR) of BDNF mRNA were PCR amplified and cloned into Renilla luciferase reporter (Promega, Madison, WI, USA) between the NotI and XhoI restriction sites. To generate Renilla luciferase reporter containing predicted target sites of miRNA-206, as well as the mutated target site #3 (Fig. 2), the sense and antisense sequences of each of the target sites were engineered to contain terminal sticky ends of the NotI and XhoI restriction sites and dimerized to be directly ligated to backbone of Renilla constructs pre-digested with restriction enzymes.

**Dual-luciferase reporter assay**

Luciferase assays were performed in F-11 cells (derived from the fusion between mouse neuroblastoma cell line N18TG2 with embryonic rat DRG neurons) using the Dual-Luciferase Reporter 1000 Assay System (Promega). Briefly, F-11 cells were plated at a density of 8000 cells/cm² on 6 cm culture dishes and co-transfected with internal control (firefly luciferase reporter) and experimental Renilla luciferase reporters using Lipofectamine 2000 (Invitrogen). Twenty-four hours after transfection, the F-11 cells were replated at a density of 5000 cells/cm² in a 24-well plate and incubated for 24 h before being transfected again with either scrambled miRNA, firefly or Renilla DsiRNAs (Integrated DNA Technologies), miR-206 mimic (Invitrogen). DsiRNA is an siRNA control for the effective knockdown of luciferase genes and miRNA mimic is chemically modified miRNA-like RNA that is designed to copy the functionality of mature endogenous miRNA upon transfection. Both firefly and Renilla luciferase activities were measured sequentially from the cell lysate and the normalized values (Renilla activity/firefly activity) were used for analysis to minimize experimental variability between replicates.

**DRG primary neuronal culture in the modified Boyden chamber**

The modified Boyden chamber was used to physically separate axonal and somal compartments [19–21]. Briefly, 8 μm
tissue culture inserts were placed in six multiwell culture plates and doubly coated with poly-L-lysine (Sigma, St Louis, MO, USA) and laminin (Millipore, Billerica, MA, USA). DRG neurons were dissociated in collagenase and washed multiple times with DRG culture media containing 5% horse serum, 5% fetal bovine serum, 1 x Heps, 2 mM l-glutamine, 1 x N1 supplement and 10 μM AraC in Dulbecco’s modified Eagle’s medium/F-12 (Invitrogen). After transfection with miRNA-206 using the 4D-Nucleofector system (Lonza, Allendale, NJ, USA), cells were plated onto the tissue inserts and incubated for 3 days in culture at 37 °C with 5% CO₂.

**Immunoblotting**

Axonal total proteins were isolated from the tissue culture inserts by scraping the bottom surface of the membrane with a cell scraper and dispersed in modified radiomunoprecipitation assay buffer supplemented with phenylmethanesulfonyl fluoride, a protease cocktail and a phosphatase inhibitor (Sigma). Somal proteins were also processed by scraping the upper membrane. Lysates were mixed with 5 μL loading buffer (denaturing buffer), boiled for 5 min and then immediately placed on ice to denature the proteins and then loaded onto 12% SDS/PAGE gels followed by transferring onto a poly(vinylidene difluoride) membrane. After blocking in 5% non-fat milk in Tris-buffered saline with 0.1% Tween-20, the membrane was probed first with anti-BDNF (dilution 1 : 1000; Bioss Inc., Woburn, MA) overnight at 4 °C on a shaker. After washing extensively in Tris-buffered saline with 0.1% Tween-20, the membrane was incubated in a secondary antibody conjugated to horseradish peroxidase (dilution 1 : 3000; Cell Signaling Technology, Beverly, MA, USA). Horseradish peroxidase activity was visualized using an enhanced chemiluminescence prime western blotting detection reagent (GE Healthcare, Little Chalfont, UK). After developing the membrane to X-ray film, the membrane was extensively washed and probed with anti-GAPDH (dilution 1 : 3000; Cell Signaling). GAPDH served as an internal control for normalization.

**Northern blotting**

Five micrograms of total RNA was analyzed for each sample on 1% agarose gels followed by transfer to a nylon membrane. As a control, 5 μg of somal RNA was incubated with 100 μg of RNase A (Qiagen, Valencia, CA, USA) at 37 °C for 30 min prior to electrophoresis. Northern blotting was performed as described previously [22]. Briefly, after UV crosslinking, the blot was hybridized with biotin-labeled antisense probe specific for BDNF coding region and detected by the Chemiluminescent Nucleic Acid Detection Module (Pierce, Rockford, IL, USA). Biotin-labeled probe was synthesized using a Biotin RNA Labeling Mix (Roche, Basel, Switzerland) during in vitro transcription with the Riboprobe® In Vitro Transcription Systems (Promega).

---

**Fig. 2.** miRNA-206 specifically downregulates BDNF mRNA with a long 3’ UTR. (A) Dual-luciferase assays showed a significant reduction in the luciferase activities of vectors fused to a long 3’ UTR by miRNA-206. *P < 0.05 by one-way ANOVA with Bonferroni post-hoc comparisons. Error bars represent the SD (n = 3). (B) miRNA-206 failed to affect the luciferase activity of vectors fused to a short 3’ UTR. One-way ANOVA with Bonferroni post-hoc comparisons. Error bars represent the SD (n = 3). (C) Transfection of miRNA-206 reduced the luciferase activities of vectors containing #3 target site but failed when the seed sequences of the #3 sites were mutated, revealing the target specificity. **P < 0.01 by Student’s t-test, Error bars represent the SD (n = 4).
Fluorescence recovery after photobleaching (FRAP)

Myristoylation tag (myr) was added to the GFP or mCherry to limit cellular free diffusion because myr tag will target the newly synthesized reporter protein to the adjacent membrane. DRG neurons were transfected with either myr-eGFP-BDNF long 3’ UTR, myr-mCherry-BDNF short 3’ UTR construct, or both, using the 4D-Nucleofector system (Lonza) and plated on glass-bottom 35 mm culture dishes that were doubly coated with poly-L-lysine and laminin. Transfected DRG cultures were analyzed 48–72 h after transfection for intra-axonal eGFP or mCherry fluorescence. A LSM 880 confocal microscope fitted with an environment chamber (Carl Zeiss, Oberkochen, Germany) was used for photobleaching and monitoring recovery of fluorescence. Axons longer than 400 μm in length from the cell body were carefully selected for the FRAP experiments to minimize the diffusion of GFP or mCherry from the cell body during recovery. Terminal axons were imaged every 30 s for 10 min with a 488 nm or a 594 nm laser to establish a baseline fluorescence intensity of eGFP or mCherry, respectively (prebleach). A region of interest (ROI) of terminal axons was exposed to 100% power of the 488 nm or 594 nm laser for 35 repeats for photobleaching (bleach). The recovery of fluorescence within the photobleached environment chamber (Carl Zeiss, Oberkochen, Germany) was used for photobleaching and monitoring recovery of fluorescence. Axons longer than 400 μm in length from the cell body were carefully selected for the FRAP experiments to minimize the diffusion of GFP or mCherry from the cell body during recovery. Terminal axons were imaged every 30 s for 10 min with a 488 nm or a 594 nm laser to establish a baseline fluorescence intensity of eGFP or mCherry, respectively (prebleach). A region of interest (ROI) of terminal axons was exposed to 100% power of the 488 nm or the 594 nm laser for 35 repeats for photobleaching (bleaching). The recovery of fluorescence within the photobleached ROI was then monitored by acquiring images every 60 s under the same 488 nm or 594 nm laser sets as in the prebleach for a total of 30 min (postbleach). Cycloheximide (100 μg mL⁻¹) was added as a translational inhibitor to ensure that fluorescence recovery depends on local protein synthesis. Recovery was quantified from n = 7 neurons using IMAGEJ (NIH, Bethesda, MD, USA) to calculate average pixels per μm² in the ROIs of the raw confocal images.

Statistical analysis

PRISM, version 5 (GraphPad Software Inc., San Diego, CA, USA) was used for all of the statistical analyses. ddPCR and the luciferase assay were analyzed using Student’s t-test and one-way ANOVA with Bonferroni post-hoc comparisons, respectively.

Results

BDNF mRNA with a long 3’ UTR is present at low abundance in distal axons of adult rat sensory neurons

Two different 3’ UTR variants of BDNF mRNA have been identified and the 3’ UTR has been reported to be responsible for their subcellular localization pattern [1,10–12]. However, most of the earlier studies were performed in dendrites of central nervous system neurons, prompting debate about the abundance of localized BDNF mRNA with a long 3’ UTR in distal axons. Therefore, we examined the abundance and localization of endogenous BDNF mRNA with a long 3’ UTR in the distal axons of adult rat sensory neurons. First, to re-evaluate subcellular localization of the long 3’ UTR variant of BDNF mRNA in distal axons of DRG neurons in vivo, sciatic nerve axoplasm was mechanically extracted from the nerve of adult rats using the mechanical squeezing method that we optimized previously [17]. To determine the purity of the axoplasmic RNA, extended (40 cycles) RT-PCR was carried out to assess glial and cell body contamination (Fig. 1A). H1F0 and MAP2 mRNAs are shown to be excluded from axons [20] and thus are used to determine the contamination of cell body-restricted mRNAs into axons. Levels of glial-specific mRNAs (GFAP and ErbB3) were also tested to ensure minimal contamination from Schwann or satellite cells. β-actin was included to confirm the presence of mRNA in the extracted samples (Fig. 1A) because its presence in both the axon and soma of sensory neurons has been demonstrated previously [18–21]. As shown in Fig. 1A (bottom), extended RT-PCR using an equivalent amount of cDNAs from sciatic nerve (axon) and DRG (soma) only demonstrated a positive PCR product for β-actin, whereas glial cell or cell body-restricted mRNAs were undetectable, indicating highly enriched axonal RNAs.

After determining the purity, the presence of BDNF mRNA with a long 3’ UTR within the distal axons was confirmed by semiquantitative RT-PCR using specific primers for the long 3’ UTR (Fig. 1B). Consistent with previous studies showing the presence of a long 3’ UTR variant of BDNF mRNA in the dendrites of central nervous system neurons [12], we detected BDNF mRNA with a long 3’ UTR in all samples, including sciatic nerve axoplasm. The lower intensity of the PCR amplicon for BDNF mRNA with a long 3’ UTR from sciatic axoplasm also suggested a relatively low abundance of the transcript in axons.

To determine whether axonal BDNF mRNA with a long 3’ UTR is differentially distributed in axons and cell bodies, we used droplet digital PCR technology. Similar to previous studies [10,23], the relative number of copies for the long 3’ UTR to the total BDNF in cell body sample was calculated as a ratio of 1:4 (2.8 copies vs. 11.4 copies). Next, to gain an estimate of the relative abundance of BDNF mRNA with a long 3’ UTR in axons to that in cell bodies, the number of copies of BDNF mRNA was first normalized to that for amphotericin mRNA to account for varying amounts in axons and cell bodies between experimental samples [18,19]. We then contrasted the level of
axonal BDNF mRNA to that of somal BDNF mRNA. We also included specific primer sets for peripheral sensory neuron-specific sodium channels including Nav1.7, Nav1.8 and Nav1.9 isoforms as positive markers for sensory neurons [24,25]. As shown in Fig. 1C, the relative level of axonal BDNF transcript with a long 3’ UTR was approximately 1.8-fold higher compared to that measured in cell body, suggesting a preferential localization of BDNF mRNA with a long 3’ UTR to distal axons. Note that the lower ratio could be interpreted as either the absolute copy number or relative abundance of target mRNA being lower compared to the soma. Both Gap43 and Neuritin (Nrn1) mRNAs have been shown to localize to the axons of sensory neurons [20,21,26–28] and so the relatively low ratio indicates that the soma level is relatively larger than those of the axons. Taken together, these results suggest that the long 3’ UTR enables preferential localization of BDNF mRNA into axons.

Although our cRNA probe hybridization protocol to visualize the endogenous BDNF mRNA with a long 3’ UTR plagued the fluorescence in situ hybridization signal in our hands, we carried out northern blot analyses of total RNAs from DRG soma and sciatic axoplasm using RNA probes derived from the BDNF coding region. Both the long and short BDNF mRNAs were present in all examined samples (Fig. S1). In this experiment, we also included RNase A-treated somal RNA sample and used as a negative control to assess the signal specificity.

### The long 3’ UTR variant of BDNF mRNA is differentially regulated by miRNA-206

Although two 3’ UTR variants of BDNF mRNA are reported to confer distinct subcellular distribution of the isoforms and functions in neurons [12], we are only beginning to understand the scope of molecular mechanisms that enable subcellular region-specific post-transcriptional regulation of mRNA isoforms, which contributes to the functional diversity between subcellular locales within a neuron. Targeting of brain BDNF mRNAs with miRNA-206 was first demonstrated in Tg2576 Alzheimer disease transgenic mice [16]. Because a longer 3’ UTR contains more chances of having a miRNA target site(s), we hypothesized that BDNF mRNA with a long 3’ UTR variant present in distal axons of sensory neurons is specifically subjected to a differential regulation by miRNA-206, compared to a short variant.

To directly contrast potential miRNA-206 target sites predicted in a long 3’ UTR variant vs. a short 3’ UTR, two Internet-based algorithms, TargetScan and miRanda, were used and found three vs. one putative target sites of miRNA-206 in the long and short 3’ UTR, respectively (Fig. S2). To test the target specificity of miRNA-206, we used luciferase reporters fused to either a short or long 3’ UTR variants of BDNF mRNA. Transient overexpression of cells with miRNA-206 significantly reduced the luciferase activities in the cells transfected with the vectors containing a long 3’ UTR variant at a concentration of 60 nM (Fig. 2A). By contrast, when the cells were transfected with the reporter vector bearing a short 3’ UTR, overexpression of miRNA-206 failed to change the luciferase activity (Fig. 2B). To test further the specificity of the target sites within a long 3’ UTR, we repeated the assay with luciferase vectors bearing the individual putative target sites. As shown in Fig. 2C, only the target site #3 showed a significant reduction in the luciferase activity by miRNA-206. However, when the seed sequence of the target site #3 was mutated, miRNA-206 did not change luciferase activity. These results indicated that miRNA-206 differentially regulates a specific BDNF mRNA variant via recognition of the target site #3 present only in the long 3’ UTR. It is worth noting that we detected a significant reduction in BDNF mRNA in response to miRNA-206 overexpression, which is consistent with the reduction in BDNF protein (Fig. 3B), suggesting that miRNA-206 regulates BDNF expression, at least in part, via an effect on mRNA stability in DRG neurons. Taken together, local expression of BDNF mRNA variant with a long 3’ UTR can be specifically downregulated by miRNA-206 in distal axons without affecting the counterpart with a short 3’ UTR in the cell body.

### miRNA-206 decreases BDNF protein expression in cultured adult sensory neurons

To investigate whether miRNA-206 enables a differential spatial regulation of BDNF expression at a subcellular level in a neuron, we used the modified Boyden insert to physically separate the axonal compartment and cell body compartment. DRG neurons transfected with miRNA-206 were cultured for 3 days on the tissue culture inserts doubly coated with poly-L-lysine and laminin. The axonal lysate and cell body lysates were obtained by scraping the bottom and top of the insert membrane, respectively. After the purity analysis, the somal and axonal lysates were subjected to western blot analysis to monitor BDNF protein levels (Fig. 3A). Transfection efficiencies were often very low to moderate (an average transfection efficiency of
 analyses on total lysate may underestimate the true regulatory activity of the interfering miRNA-206 that is spatial-specific. Fortunately, the transfection of miRNA-206 into DRG neurons significantly decreased BDNF protein levels by 30.1 ± 3.4% and 44.9 ± 6.1% in the cell bodies and axons, respectively, compared to those transfected with control scrambled miRNA (Fig. 3B). This difference was found to be significant (P = 0.0218) on statistical analysis by an unpaired two-tailed Student’s t-test. Taking in account the moderate transfection efficiencies of DRG neurons with miRNA-206, this result implies a plausible underestimation of differential regulation of axonal BDNF expression, and a more robust effect of miRNA-206 might be linked to its differential regulation of BDNF expression in the axonal compartment compared to that in cell body compartment. Consistent with the reduction in BDNF protein, we detected a significant reduction in total BDNF mRNA levels in response to miRNA-206 transfection (Fig. 3C), suggesting that miRNA-206 downregulates BDNF expression, at least in part, via mRNA destabilization. Taken together, these data show that miRNA-206 differentially targets BDNF mRNA variant with a long 3’ UTR from the counterpart with a short 3’ UTR.

**Discussion**

In the present study, we found that a long 3’ UTR variant of rat BDNF mRNA, which is present in distal axons of sensory neurons, is differentially regulated by miRNA-206 compared to its shorter 3’ UTR counterpart in subcellular regions of sensory neurons. The results suggest that transcripts with a longer 3’ UTR potentially harboring more miRNA-binding sites can provide a precise molecular mechanism for spatially differential downregulation in a subcellular region-specific manner.

BDNF mRNAs are polyadenylated at two alternative poly(A) sites, leading to two distinct 3’ UTR variants, a short form (0.35 kb) and a long 3’ UTR (2.9 kb), which are reported to be responsible for the distinct subcellular localization [1,10–12]. An et al. [12] previously showed that BDNF mRNA containing a short 3’ UTR variant is restricted to the soma and suggested that the localization cis-element(s) reside within the distal segment of the long 3’ UTR of BDNF mRNA. However, the substantive cis-elements are still a matter of debate because the results of other studies suggest that dendritic targeting elements are found in the short 3’ UTR [29,30]. Consistent with this notion, we detected both the long and short BDNF mRNAs in all of the samples examined,
including sciatic nerve, by northern blot analysis of total RNA (Fig. 1 and S1). Furthermore, our data from the FRAP analyses revealed a significant recovery after photobleaching in DRG neurons transfected with fluorescent reporter fused with a short 3' UTR of BDNF mRNA, as well as that fused with a long 3' UTR (Fig. S3), although the recovery level was relatively lower with the short 3' UTR compared to that with the long 3' UTR. Treating cells with translation inhibitors such as cycloheximide prior to bleaching blocked the fluorescence recovery, indicating that the recovery of fluorescence signals after photobleaching is a result of the local protein synthesis of localized reporter mRNAs. This could be explained by many factors, most significantly the differential degree of targeting capability of multiple cis-elements that control the mRNA localization in axons. Indeed, several previous studies suggest the presence of multiple cis-elements within the 3' UTR of transcripts that have a differential degree of axonal targeting capability [10,30,31]. Additionally, different experimental conditions, including differences between neurons derived from the central nervous system and the peripheral nervous system, may cause such a discrepancy, with the differential expression level of trans-acting factors such as RNA-binding proteins contributing to the complexity of the regulation of mRNA transport and translation at post-transcriptional levels. Future studies will be essential to confirm the degree of localization capability between multiple motifs in the 3' UTR.

miRNAs are short non-coding RNAs that regulate translation of mRNAs by binding to their target sequences usually within the 3' UTR in a sequence-dependent manner. Consistent with previous studies [16,32], our luciferase reporter assays and western blot analyses showed that the expression of BDNF mRNA in distal axons of sensory neurons is specifically down-regulated by miR-206. miRNA-206 is one of the most studied miRNAs and was originally considered to be vertebrate muscle specific [33,34]. However, relatively recent studies have demonstrated its expression in non-muscle tissues, including fat, liver and breast, as well as in the nervous system with respect to Alzheimer's disease, amyotrophic lateral sclerosis, cerebral ischemia, schizophrenia and regenerating nerves [16,35–40]. This suggests potential functions of miRNA-206 in the nervous system in addition to the developmental and pathological roles in muscle cells [34]. Given that both the short and long 3' UTR variants of BDNF mRNA are present in distal axons, miRNA-206 may be able to distinguish the long 3' UTR of BDNF mRNA from the short form in the process of translational control in distal axons. It is not clear yet why these two 3' UTR variants of BDNF mRNA are localized to distal axons and regulated differentially by miR-206 because our preliminary data failed to reveal biological effects of miRNA-206 transfection on DRG neurons derived from adult rats (data not shown). However, it is plausible that the long 3' UTR form of BDNF transcript encoded a protein with novel functions. The newly synthesized protein from the long variant of BDNF mRNA within axons could act as a retrograde injury signal, as shown in previous studies [41–46]. A major challenge to understanding whether locally synthesized BDNF protein in axons has a novel biological role in neurons involves monitoring the trafficking of locally synthesized protein in axons. Also, it will be interesting to determine what happens to BDNF local synthesis when the negative regulation by miR-206 is blocked.

It is estimated that more than 50% of mammalian transcripts contain alternative poly(A) sites that can lead to different 3' UTR variants [47]. Several previous studies showed that different variants of the same transcript are differentially transported to axons, suggesting the presence of sequences or elements conferring axonal targeting within the 3' UTR. However, it is unclear how the translation of these variants is differentially regulated from their counterparts with a shorter 3' UTR. The work reported in the present study suggests that variant-specific sequences contain miRNA-binding sites or sites for RNA-binding proteins, providing a unique ability for precise control of the temporal and spatial regulation of BDNF protein upon neuronal activation.

Acknowledgements

The work described in the present study was supported by the National Institute of Health (P20-GM103464, R21-NS085691, R21NS099959). The study was also partially supported by Delaware INBRE (P20-GM103446) and U54-GM104941 (DE-CTR ACCEL Pilot grant). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS, NINDS or NIH.

Author contributions

SS, HHK and SY designed the experiments. SS and SY wrote the manuscript. SS, HHK and PP extracted the RNA. SS and MP performed the sequencing and bioinformatics analyses. SS, MP and HHK performed the reporter generation, luciferase activity assays and FRAP experiments. SL performed the ddPCR.
Conflicts of interest
The authors declare no conflict of interest.

References
1 Greenberg ME, Xu B, Lu B and Hempstead BL (2009) New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci 29, 12764–12767.
2 Poo MM (2001) Neurotrophins as synaptic modulators. Nat Rev Neurosci 2, 24–32.
3 Skaper SD (2012) The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol 846, 1–12.
4 Volosin M, Song W, Almeida RD, Kaplan DR, Hempstead BL and Friedman WJ (2006) Interaction of survival and death signaling in basal forebrain neurons: roles of neurotrophins and proneurotrophins. J Neurosci 26, 7756–7766.
5 Lee J, Fukumoto H, Orne J, Klucken J, Raju S, Vanderburg CR, Irizarry MC, Hyman BT and Ingelsson M (2005) Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Exp Neurol 194, 91–96.
6 Murer MG, Yan Q and Raisman-Vozari R (2001) Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol 63, 71–124.
7 Peng S, Wuu J, Mulson EJ and Fahnstock M (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem 93, 1412–1421.
8 Qin XY, Cao C, Cawley NX, Liu TT, Yuan J, Loh YP and Cheng Y (2017) Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer’s disease: a meta-analysis study (N = 7277). Mol Psychiatry 22, 312–320.
9 Zuccato C and Cattaneo E (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5, 311–322.
10 Lau AG, Irier HA, Gu J, Tian D, Ku L, Liu G, Xia M, Fritsch B, Zheng QJ, Dingledine R et al. (2010) Distinct 3’UTRs differentially regulate activity-dependent translation of brain-derived neurotrophic factor (BDNF). Proc Natl Acad Sci U S A 107, 15945–15950.
11 Timmusk T, Palm K, Metsis M, Reintam T, Paalme V, Saarma M and Persson H (1993) Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron 10, 475–489.
12 An JJ, Gharami K, Liao GY, Woo NH, Lau AG, Vanevski F, Torre ER, Jones KR, Feng Y, Lu B et al. (2008) Distinct role of long 3’ UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. Cell 134, 175–187.
13 Ambros V (2004) The functions of animal microRNAs. Nature 431, 350–355.
14 Bartel DP and Chen CZ (2004) Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 5, 396–400.
15 Wahid F, Shehzad A, Khan T and Kim YY (2010) MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 1803, 1231–1243.
16 Lee ST, Chu K, Jung KH, Kim JH, Huh JY, Yoon H, Park DK, Lim JY, Kim JM, Jeon D et al. (2012) miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Am Neurol 72, 269–277.
17 Kim HH, Phay M and Yoo S (2016) Isolation and quantitative analysis of axonal small noncoding RNAs. In MicroRNA Technologies (Kye MJ, ed), pp. 1–13. Humana Press, Totowa, NJ.
18 Kalinski AL, Sachdeva R, Gomes C, Lee SJ, Shah Z, Houle JD and Twiss JL (2015) mRNAs and protein synthetic machinery localize into regenerating spinal cord axons when they are provided a substrate that supports growth. J Neurosci 35, 10357–10370.
19 Merianda TT, Coleman J, Kim HH, Kumar Sahoo P, Gomes C, Brito-Vargas P, Rauvala H, Blesch A, Yoo S and Twiss JL (2015) Axonal amphoterin mRNA is regulated by translational control and enhances axon outgrowth. J Neurosci 35, 5693–5706.
20 Yoo S, Kim HH, Kim P, Donnelly CJ, Kalinski AL, Vuppalanchi D, Park M, Lee SJ, Merianda TT, Perrone-Bizzozero NI et al. (2013) A HuD-ZBP1 ribonucleoprotein complex localizes GAP-43 mRNA into axons through its 3’ untranslated region AU-rich regulatory element. J Neurochem 126, 792–804.
21 Gomes C, Lee SJ, Gardiner AS, Smith T, Sahoo PK, Patel P, Thomas E, Rodriguez R, Taylor R, Yoo S et al. (2017) Axonal localization of neuritin/CPG15 mRNA is limited by competition for HuD binding. J Cell Sci 130, 3650–3662.
22 Phay M, Kim HH and Yoo S (2018) Analysis of piRNA-like small non-coding RNAs present in axons of adult sensory neurons. Mol Neurobiol 55, 483–494.
23 Will TJ, Tushev G, Kochen L, Nassim-Assir B, Cajigas JJ, Tom Dieck S and Schuman EM (2013) Deep sequencing and high-resolution imaging reveal compartment-specific localization of Bdnf mRNA in hippocampal neurons. Sci Signal 6, rs16.
24 Yang Y, Mis MA, Estacion M, Dib-Hajj SD and Waxman SG (2018) NaV1.7 as a pharmacogenomic target for pain: moving toward precision medicine. Trends Pharmacol Sci 39, 258–275.
25 Waxman SG and Zamponi GW (2014) Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci 17, 153–163.

26 Merianda TT, Gomes C, Yoo S, Vuppulanchi D and Twiss JL (2013) Axonal localization of neureitin/CPG15 mRNA in neuronal populations through distinct 5′ and 3′ UTR elements. J Neurosci 33, 13735–13742.

27 Bird CW, Gardiner AS, Bolognani F, Tanner DC, Chen CY, Lin WJ, Yoo S, Twiss JL and Perrone-Bizzozero N (2013) KSRP modulation of GAP-43 mRNA stability restricts axonal outgrowth in embryonic hippocampal neurons. PLoS ONE 8, e79255.

28 Donnelly CJ, Park M, Spillane M, Yoo S, Pacheco A, Gomes C, Vuppulanchi D, McDonald M, Kim HH, Merianda TT et al. (2013) Axonally synthesized beta-actin and GAP-43 proteins support distinct modes of axonal growth. J Neurosci 33, 3311–3322.

29 Ma B, Culver BP, Baj G, Tongiorgi E, Chao MV and Tanese N (2010) Localization of BDNF mRNA with the Huntington’s disease protein in rat brain. Mol Neurodegener 5, 22.

30 Oe S and Yoneda Y (2010) Cytoplasmic polyadenylation element-like sequences are involved in dendritic targeting of BDNF mRNA in hippocampal neurons. FEBS Lett 584, 3424–3430.

31 Vuppulanchi D, Coleman J, Yoo S, Merianda TT, Yadhati AG, Hossain J, Blesch A, Willis DE and Twiss JL (2010) Conserved 3′-untranslated region sequences direct subcellular localization of chaperone protein mRNAs in neurons. J Biol Chem 285, 18025–18038.

32 Miura P, Amirouche A, Clow C, Belanger G and Jasmin BJ (2012) Brain-derived neurotrophic factor expression is repressed during myogenic differentiation by miR-206. J Neurochem 120, 230–238.

33 McCarthy JJ (2008) MicroRNA-206: the skeletal muscle-specific myomiR. Biochim Biophys Acta 1779, 682–691.

34 Novak J, Kruziak P, Bienertova-Vasku J, Slaby O and Novak M (2014) MicroRNA-206: a promising theranostic marker. Theranostics 4, 119–133.

35 Hansen T, Olsen L, Lindsey M, Jakobsen KD, Ullum H, Jonsson E, Andreassen OA, Djurovic S, Melle I, Agartz I et al. (2007) Brain expressed microRNAs implicated in schizophrenia etiology. PLoS ONE 2, e873.

36 Kusuda R, Cadetti F, Ravaneli MI, Sousa TA, Zanon S, De Lucca FL and Lucas G (2011) Differential expression of microRNAs in mouse pain models. Mol Pain 7, 17.

37 Phay M, Kim HH and Yoo S (2015) Dynamic change and target prediction of axon-specific microRNAs in regenerating sciatic nerve. PLoS ONE 10, e0137461.

38 Walden TB, Timmons JA, Keller P, Nedergaard J and Cannon B (2009) Distinct expression of muscle-specific microRNAs (myomirs) in brown adipocytes. J Cell Physiol 218, 444–449.

39 Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, Bassel-Duby R, Sanes JR and Olson EN (2009) MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 326, 1549–1554.

40 Zhong D, Huang G, Zhang Y, Zeng Y, Xu Z, Zhao Y, He X and He F (2013) MicroRNA-1 and microRNA-206 suppress LXRalpha-induced lipogenesis in hepatocytes. Cell Signal 25, 1429–1437.

41 Ben-Yaakov K, Dagan SY, Segal-Ruder Y, Shalem O, Vuppulanchi D, Willis DE, Yudin D, Rishal I, Rother F, Bader M et al. (2012) Axonal transcription factors signal retrogradely in lesioned peripheral nerve. EMBO J 31, 1350–1363.

42 Cox LJ, Hengst U, Gurskaya NG, Lukyanov KA and Jaffrey SR (2008) Intra-axonal translation and retrograde trafficking of CREB promotes neuronal survival. Nat Cell Biol 10, 149–159.

43 Harrington AW and Ginty DD (2013) Long-distance retrograde neurotrophic factor signalling in neurons. Nat Rev Neurosci 14, 177–187.

44 Ji SJ and Jaffrey SR (2012) Intra-axonal translation of SMAD1/5/8 mediates retrograde regulation of trigeminal ganglia subtype specification. Neuron 74, 95–107.

45 Yudin D, Hanz S, Yoo S, Iavnilovitch E, Willis D, Gradus T, Vuppulanchi D, Segal-Ruder Y, Ben-Yaakov K, Hieda M et al. (2008) Localized regulation of axonal RanGTPase controls retrograde injury signaling in peripheral nerve. Neuron 59, 241–252.

46 Perry RB, Doron-Mandel E, Iavnilovitch E, Rishal I, Dagan SY, Tsory M, Coppola G, McDonald MK, Gomes C, Geschwind DH et al. (2012) Subcellular knockout of importin beta1 perturbs axonal retrograde signaling. Neuron 75, 294–305.

47 Tian B, Hu J, Zhang H and Lutz CS (2005) A large-scale analysis of mRNA polyadenylation of human and mouse genes. Nucleic Acids Res 33, 201–212.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Fig. S1. BDNF mRNAs with a short and a long 3′ UTR were present in sciatic nerve.

Fig. S2. Schematic of 3′ UTR variants of BDNF mRNAs, a long 3′ UTR and a short 3′ UTR.

Fig. S3. BDNF 3′ UTR is sufficient for localization and translation of a reporter mRNA in axons of sensory neurons.